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Abstract
Background Increased circulating cortisol levels have
been associated with severity of atherosclerosis. Low-grade
systemic thrombogenicity plays a major role in the initia-
tion and progression of coronary disease. We hypothesized
a direct relationship between cortisol and hemostasis fac-
tors related to a prothrombotic state in coronary artery
disease.
Methods We measured morning serum cortisol and acti-
vated clotting factor VII, fibrinogen, von Willebrand factor
antigen, and plasminogen activator inhibitor-1 activity in
285 women (56 ± 7 years) between 3 and 6 months after
an acute coronary event. To test whether the relationship
between cortisol and hemostasis factors would be inde-
pendent, statistical adjustment was made for demographic,
biomedical, life style, and psychosocial variables.
Results Higher serum cortisol levels predicted higher
fibrinogen (b = .17, P = .001) and higher von Willebrand
factor (b = .16, P = .008), all independently of covari-
ates, including C-reactive protein, which was also an
independent predictor of fibrinogen (b = .20, P = .001)
and von Willebrand factor (b = .16, P = .004). Higher
levels of vital exhaustion were associated with higher
levels of activated clotting factor VII independently of
covariates and depression (b = .18, P = .045). Cortisol
showed crude correlations with vital exhaustion (r = .14,
P = .022) and with depression (r = .13, P = .043) but did
not mediate the relationship between psychosocial vari-
ables and hemostatic factors.
Conclusions Morning serum cortisol showed a modest
but independent association with prothrombotic activity in
women with coronary artery disease suggesting that
increased cortisol levels might contribute to atherosclerosis
via eliciting a hypercoagulable state.
Keywords Cortisol  Cardiovascular disease 
Hemostasis  Inflammation
Introduction
An exaggerated physiological stress response to a variety
of environmental stimuli and as mediated by the hypotha-
lamic-pituitary adrenal (HPA) axis may contribute to
cardiovascular disease [1, 2]. During the first hours of an
acute myocardial infarction (AMI), hyperactivity of the
HPA axis is evident as regards cortisol spillover [3–5].
Higher cortisol levels in AMI patients at hospital admission
predicted extent of myocardial damage [5, 6], risk of
recurrent non-fatal MI [7], and mortality [6]. Cortisol
excess may also exert cardiovascular peril in patients with
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stable coronary artery disease (CAD) who showed more
severe coronary sclerosis with higher circulating cortisol
levels [8–10].
The mechanisms through which circulating cortisol
contributes to atherosclerosis are likely manifold. HPA axis
dysregulation is associated with cardiovascular disease risk
factors clustering in the metabolic syndrome such as
truncal obesity, dyslipidemia, and high blood pressure [11].
A prothrombotic state, as characterized by elevated circu-
lating fibrinogen and plasminogen activator inhibitor
(PAI)-1, also belongs to the metabolic disturbances perti-
nent to cardiovascular disease [12]. However, the rela-
tionship between cortisol and low-grade systemic
thrombogenicity playing a major role in the pathogenesis
of atherosclerosis and onset of acute ischemic events [13]
has not been investigated in CAD patients.
CAD is under-researched in women relative to men [14].
In this study, we investigated female patients because of a
particular paucity of data on women’s psychosocial and
other cardiovascular risk factors, including hemostatic
measures. We studied a relatively young group of women
coronary patients because their ailments can be viewed as
premature, and not as a sign or symptom of the ordinary
ageing process. We hypothesized that morning cortisol
levels would be associated with a prothrombotic state, as
defined by increased plasma levels of four hemostasis
factors, i.e. activated clotting factor VII (FVIIa), fibrino-
gen, von Willebrand factor (VWF), and PAI-1 in women
with CAD. The reasoning for this hypothesis was three-
fold. First, all of these factors independently predicted
coronary events in prospective large-scale epidemiological
studies [15–16]. Second, patients with Cushing’s disease
confer a prothrombotic state characterized by high levels of
fibrinogen, VWF, and PAI-1 [17–19]. This hypercoagula-
bility is thought to be a consequence of excessive endog-
enous cortisol production and to increase cardiovascular
risk of Cushing patients [20]. Third, exogenous glucocor-
ticoid administration increases procoagulant activity (e.g.
FVII, fibrinogen, and VWF) and dampens fibrinolytic
activity in humans [21–24]. We further investigated
whether the relationship between cortisol and hemostasis
factors is independent of demographic, medical, and life
style covariates commonly affecting hemostatic function.
Because hemostasis and inflammation are highly interact-
ing in promoting the atherosclerotic process [25], we
particularly aimed to investigate whether the cortisol-
hemostasis relationship is independent of low-grade
proinflammatory activity as measured by serum levels of
C-reactive protein (CRP).
Basal cortisol levels in stable CAD are unlikely influ-
enced by the acute phase of MI because cortisol rise during
AMI usually returns to normal within one week post-MI [4,
26]. In stable CAD, possible correlates of elevated basal
cortisol levels are depressed mood [27] and, as previously
shown in the sample of women patients investigated in this
study, feelings of vital exhaustion [9]. Depression and vital
exhaustion are both prevalent in patients with CAD and are
independent CAD risk factors [28]. Depressed individuals
have demonstrated elevated levels of fibrinogen, FVII, and
PAI-1 [29–31]. Similarly, exhausted subjects show
increased levels of fibrinogen and PAI-1 [32, 33]. We
therefore also investigated whether cortisol relates to
hemostasis factors independent of depression and vital
exhaustion or, alternatively, whether cortisol is a mediator
of the relationship between hemostasis and psychosocial
factors.
Materials and methods
Patients and study design
The Ethics Committee of the Karolinska Institutet
approved the study protocol and all subjects provided
informed consent. As previously described in more detail
[34], we included women patients aged £ 65 years who
were hospitalized for AMI or unstable angina pectoris
(UAP) during a 3-year period between 1991 and 1994. The
diagnosis of AMI was made following WHO criteria [35]
of typical chest pain, cardiac enzyme patterns, and/or
diagnostic ECG changes as classified by the Minnesota
code [36]. UAP was defined as new onset of severe AP, or
deterioration of known stable AP in the 4 weeks before
hospital admission [37]. A total of 292 women (110 AMI,
182 UAP) were enrolled and examined at the research
clinic as outpatients between 3 and 6 months after dis-
charge from the hospital. At this time, they were consid-
ered to be in a stable cardiac and metabolic condition and
without acute phase reaction influencing laboratory mea-
surements, including hemostasis factors and CRP. For the
present study, we performed analyses on 285 women with
an acute coronary event who had complete data in terms of
cortisol levels, CRP, and at least one of the four hemostasis
factors measured. Although not formally assessed, there
was not much clinical co-morbidity in this relatively young
group of women patients.
Demographic and health characteristics
Detailed assessment of demographic, medical, and lifestyle
measures has previously been described [34]. Menopausal
status, body mass index (BMI) and blood pressure (BP)
were determined by standard methods. Mean BP was
computed by the formula (2/3 * diastolic BP) + (1/3 *
systolic BP). Medication (aspirin, oral anticoagulants) was
abstracted from hospital charts and verified upon arrival at
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the research clinic. Smoking habits, physical activity dur-
ing leisure time categorized as sedentary or active, and
daily alcohol intake were assessed by standard question-
naires.
Psychosocial measures
Vital exhaustion was measured by means of an early ver-
sion of the Maastricht Questionnaire [38] that was pre-
dictive for first-time MI in women [39] and new cardiac
events in men after percutaneous transluminal coronary
angioplasty [40]. The exhaustion scale comprises 19 items
scored with 1 (‘‘no’’), 2 (‘‘don’t know’’), or 3 (‘‘yes’’) and
essentially asks about unusual fatigue, increased irritabil-
ity, and feelings of demoralization. Items are summed to
create a total exhaustion score, with higher scores referring
to higher levels of exhaustion (range 19 to 57). In 32
patients, missing items were substituted by the person’s
mean of all completed items. Data imputation was not
performed in four patients who had less than half of items
present [41] yielding a total of 281 patients with a complete
vital exhaustion sum score for analyses.
Depressive symptoms were measured by means of a
previously published 10-item questionnaire [42] of which
we excluded the item asking about sexual activity to
potentially increase response rate. The current version thus
included 9 items with yes and no answers as alternatives.
The yes answers were summed with a high score indicating
high degree of depressive symptom level (range 0 to 9). Of
the 285 patients, 23 failed to adequately complete the
questionnaire (i.e., answered fewer than 5 items). We
imputed scores for an additional 25 patients who had at
least five items present [41], yielding 262 patients with a
complete depression sum score for analyses.
Although vital exhaustion and depression share con-
ceptual similarities like lack of energy, increased irrita-
bility, and demoralization, the two constructs show also
some important differences [28]. For instance, sadness,
guilt, and feelings of worthlessness are characteristics of
depression and do not belong to the definition criteria of
exhaustion [43]. Applying factorial analyses we previ-
ously showed that depression and vital exhaustion con-
stitute distinct psychological concepts in healthy
individuals [44].
Laboratory analyses
After an overnight fast and 5-min supine rest, blood sam-
ples were obtained between 8 am and 10 am, when it was
assumed that the cortisol awakening rise had declined [45].
For determining hemostatic factors, venous blood was
drawn without stasis by antecubital, direct venipuncture
into vacuum tubes containing 0.13 mol/l trisodium citrate
(9:1 blood/citrate, vol/vol). Samples were immediately
centrifuged at room temperature at 2,000 · g for 15 min
and plasma was stored at –70 C until further analyses.
FVIIa was determined by a clotting assay using soluble
recombinant truncated tissue factor (a gift from Professor
James H. Morrissey, University of Illinois at Urbana-
Champaign, Urbana, IL) [46]. Fibrinogen was measured by
a polymerization rate method [47]. VWF:Ag was analyzed
by an enzyme-linked immunosorbent assay (Asserachrom
Stago, Asnie`res, France). PAI-1 activity was determined by
a functional spectrophotometric method (Biopool AB,
Umea, Sweden). Inter-assay and intra-assay coefficients of
variation (CV) were 4% for fibrinogen, 2% for vWF:Ag,
< 10% for FVIIa, and < 12% for PAI-1 activity.
For the determination of serum total cholesterol, glu-
cose, CRP, and cortisol, fasting venous blood was drawn
into serum-separated tubes and centrifuged at 3,000 · g
for 10 min; serum was frozen and stored at –70 C.
Cholesterol was determined using CHOD-PAP enzymatic
methods with reagents from Boehringer Mannheim
(Germany) and measured with an automated multichannel
analyzer [48]. Glucose was analyzed by the GOD-PAP
method [49]. CRP was determined using a turbidimetric
immunoassay, standardized against WHO, yielding values
between 1–120 mg/L (CVs £ 12%). Cortisol was measured
by standardized radioimmunoassay [50]. All cortisol sam-
ples were analysed in duplicate and mean values were
computed; inter- and intra-assay CVs were £ 20% and
£ 10%, respectively [51].
Statistical analysis
Data were analysed using SPSS 13.0 software (SPSS Inc.,
Chicago, IL, USA). All testing was two-tailed with
P £ .05. Because of a non-normal distribution
(Kolmogorov-Smirnov Test), FVII, fibrinogen, and VWF
values were logarithmically transformed and PAI-1 values
were square-root transformed. For glucose, CRP, cortisol,
and depression values we applied Blom normal score
transformation because neither logarithmic nor square root
transformation yielded a normal distribution of these
measures. For clarity, figures show original cortisol values.
Pearson correlations quantified the bivariate relationship
between two variables.
To investigate the predictive value of cortisol for levels
of hemostasis measures, we conducted hierarchical linear
regression analyses. In these analyses, we entered in Block
1 thirteen a priori covariates potentially affecting hemo-
stasis, namely age, index event, menopausal status, medi-
cation (aspirin, oral anticoagulants), lifestyle factors
(smoking status, physical activity, alcohol consumption),
metabolic factors (BMI, cholesterol, mean BP, glucose),
and CRP. Cortisol was entered in Block 2. In a next set of
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analyses, psychosocial factors (vital exhaustion, depres-
sion) were entered separately and together in Block 2 to
test whether these would affect the relationship between
cortisol levels and hemostasis measures. In the case of
statistically significant effects, we also computed effect
size measure (Cohen’s f2) to provide an estimate of the
clinical significance of these relationships. By convention,
f2 effect sizes of 0.02, 0.15, and 0.35 are considered small,
medium, and large, respectively [52].
To statistically account for multiple comparisons
between cortisol levels and four hemostasis factors, we
applied Bonferroni correction with significance level set at
P < .013. We used the procedures described by Baron and
Kenny [53] to test the potential mediating role of cortisol




The demographic, health, and laboratory characteristics of
the 285 female patients with stable CAD, the distribution
of these variables, and occasionally missing data are
summarized in Table 1.
Bivariate correlation analysis
Laboratory measurements
Except from the relationship between FVII and VWF, all
hemostatic factors showed positive correlations with each
other (r’s between .13 and .40, p’s between .031 and
Table 1 Characteristics of 285
women with coronary artery
disease
Data were missing for
menopausal status in three
subjects (1%), for physical
activity in four subjects (1%),
and for alcohol consumption in
11 subjects (4%)
N % Mean SD Median Range
Age (years) 285 56.0 7.0 57.0 30–66
Index event
Acute myocardial infarction 107 37%
Unstable angina pectoris 178 63%
Menopausal status
Premenopausal 63 22
Postmenopausal with HRT 33 12
Postmenopausal without HRT 186 65
Aspirin 200 70









£5 g/d (light drinker) 194 68
>5 g/d (moderate drinker) 80 28
Body mass index (kg/m2) 285 27.0 4.4 26.6 18.6–42.3
Total serum cholesterol (mmol/l) 285 6.5 1.2 6.4 3.2–11.4
Fasting serum glucose (nmol/l) 285 5.8 3.3 4.9 2.9–21.9
Mean blood pressure (mmHg) 284 91.5 12.5 89.7 64.7–134.3
Serum C-reactive protein (mg/l) 285 3.8 5.4 3.0 1.0–57.0
Morning serum cortisol (nmol/l) 285 170.2 45.4 162.0 93.0–303.0
Vital exhaustion score 281 39.1 8.5 39.0 19.0–57.0
Depression score 262 3.9 2.9 4.0 0–9.0
Activated FVII (ng/ml) 272 1.29 0.34 1.28 0.44–2.42
Fibrinogen (g/l) 285 3.66 0.81 3.50 1.40–7.20
VWF antigen (IU/ml) 285 1.50 0.76 1.31 0.62–7.32
PAI-1 activity (IU/ml) 285 15.0 14.2 11.0 0–87.0
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<.001). Cortisol correlated with fibrinogen (r = .19,
p = .002; Fig. 1, Panel A) and with VWF (r = .17,
P = .004; Fig. 1, Panel B) but not significantly so with
FVII and PAI-1. CRP showed significant associations with
fibrinogen (r = .27, P < .001), with VWF (r = .17,
P = .004), and with PAI-1 (r = .16, P = .009) but not with
FVII and cortisol.
Psychosocial factors
Cortisol showed a positive relationship with total scores of
vital exhaustion (r = .14, P = .022) and of depressed mood
(r = .13, P = .043). In contrast, psychosocial factors were
not significantly correlated with any hemostatic factor and
with CRP. Because mediational tests require significant
relationships between the independent and dependent
variables, cortisol was no longer considered a mediator of
the relations between psychosocial and hemostatic factors,
although we continued to control for psychosocial factors
in our multi-variate models.
Hierarchical linear regression analysis
Predictors of hemostatic factors
Table 2 shows results of the four regression models with
adjustment made for 13 covariates in one block. All models
were significant explaining between 18% and 35% of the
variance in the respective hemostatic factor.
There were several independent relationships between
hemostatic factors and life style variables and metabolic
indices. Lower levels of physical activity and of alcohol
consumption were associated with higher levels of fibrin-
ogen and VWF. Metabolic factors were directly associated
with higher FVII and PAI-1 values.
The significant relationships between hemostatic factors
and CRP and cortisol, respectively, were independent of all
covariates and also of each other. Higher CRP levels pre-
dicted higher fibrinogen levels (P = .001; f2 = 0.04) and
higher VWF levels (P = .009; f2 = 0.03). Higher cortisol
levels also predicted higher levels of fibrinogen (P = .004;
f2 = 0.03) and of VWF (P = .008; f2 = 0.02).
Role of psychosocial factors
Next we tested whether considering psychosocial factors in
models would affect the independent relationships between
hemostatic factors and CRP and cortisol, respectively.
However, significance levels of these relationships were
maintained when exhaustion and depression were entered
into equations either separately or together in Block 2 (data
not shown in detail).
Vital exhaustion emerged as an independent predictor of
FVII when controlling for depression (b = .18, P = .045;
f2 = 0.02), whereas exhaustion and depression were not
independent predictors of fibrinogen, VWF, and PAI-1.
Discussion
We found evidence for our primary hypothesis of a rela-
tionship between circulating cortisol levels and thrombo-
genic activity. We showed that morning serum cortisol
levels are directly associated with plasma levels of fibrin-
ogen and VWF compatible with the notion that HPA axis
activity directly relates to a prothrombotic state in women
with stable CAD. At the time when we conducted our
study, one-time determination of cortisol in the morning
was a common method to assess HPA axis functioning,
whereas measurement of diurnal cortisol activity has now
become the standard procedure for this purpose [54].






































Fig. 1 Higher cortisol levels correlated significantly with higher
levels of fibrinogen (r = .19, n = 285; Panel A) and with higher levels
of VWF antigen (r = .17, n = 285; Panel B)
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Nonetheless, our findings appear to be robust because the
association with hemostatic factors was seen with one
single measurement of morning cortisol. The relationship
between cortisol and hemostatic factors maintained sig-
nificance even when controlling for a reasonable set of
correlates of hemostatic function. Importantly, although
CRP was independently associated with fibrinogen and
VWF in its own right, adjustment for CRP as a proxy
measure of systemic inflammation did not affect the rela-
tionship between cortisol and hemostasis.
Contrary to our primary hypothesis, FVII and PAI-1
were unrelated to cortisol levels. Metabolic factors pre-
dicted PAI-1 and FVII apparently stronger than did corti-
sol. Unique variances in hemostasis factors explained by
cortisol were rather modest as compared to variances
explained by BMI, total cholesterol, and glucose, respec-
tively. Some authors indeed advocate that PAI-1 is to be
viewed as a cardiovascular risk factor only because of its
strong relation to the metabolic syndrome [55]. In line with
this reasoning, we previously showed that the direct asso-
ciation between overnight cortisol excretion in urine and
morning PAI-1 levels became nonsignificant particularly
when controlling for metabolic factors [56].
Metabolic effects of circulating cortisol on the hemo-
static system could be of clinical importance. Recent meta-
analyses suggest that the predictive value of hemostatic
factors for cardiovascular events is most robust in terms of
fibrinogen [15] and VWF [16] both associated with serum
cortisol in our patients. Our study is unable to prove a
causal relationship between cortisol and fibrinogen and
VWF, respectively, in CAD patients which only a
longitudinal design could substantiate if cortisol and
hemostatic factor levels turned out to covary over time. In
spite of its cross-sectional nature, our study is compatible
with basic research showing that glucocorticoids enhance
production of hemostatic factors on the cellular and protein
level. Glucocorticoids induced fibrinogen-mRNA expres-
sion in cultured hepatocytes [57] and VWF-mRNA
expression in cultured human umbilical endothelial cells
[24], respectively. Moreover, exogenous administration of
therapeutic dosages of dexamethasone for a few days
resulted in increased plasma levels of fibrinogen [21] and
of VWF [23]. Such procoagulatory mechanisms might help
explain the previously observed relationship between
higher circulating cortisol levels and more severe athero-
sclerosis, including in our female patients [8, 9], and
between a greater awakening cortisol response and
atherosclerosis progression in women [58].
Vital exhaustion and depression did not affect the rela-
tionship between cortisol and hemostatic factors. However,
we found that vital exhaustion was an independent pre-
dictor of FVII. The latter is a novel finding that adds to the
growing literature on a prothrombotic state in subjects who
are exhausted [28, 32, 33]. The relationship between
exhaustion and FVII was not mediated by cortisol
suggesting that other stress-mediating systems might be
involved [1].
We acknowledge the following limitations of our study.
Accurate assessment of HPA axis activity and of CRP was
compromised by our methodology. Morning cortisol levels
are influenced by a variety of factors and do not necessarily
reflect the diurnal course of HPA axis activity which
Table 2 Regression model for
hemostasis measures





significance levels: * P £ .05,
** P £ .01, *** P £ .001 VWF,
von Willebrand factor; PAI-1,
plasminogen activator
inhibitor-1
Covariates entered Hemostatic factor
Factor VII Fibrinogen VWF PAI-1
Age .03 .02 .11 –.17*
Index event –.07 .11 .15* < .01
Menopausal status –.03 .04 .06 .03
Aspirin .05 < –.01 –.03 –.03
Oral anticoagulants –.25*** .09 < .01 –.03
Smoking status < –.01 .09 .06 .12*
Physical activity –.03 –.12* –.13* .03
Alcohol use –.03 –.14* –.15* –.03
Body mass index .18** .11 .08 .37***
Total cholesterol .25*** .17** .11 .15**
Mean blood pressure –.01 .02 .04 < –.01
Glucose .08 .01 –.05 .27***
C-reactive protein .06 .20*** .16** .08
Cortisol –.09 .17** .16** .04
Df F14,237 = 3.9 F14,250 = 5.2 F14,250 = 3.9 F14,250 = 9.6
Variance explained by R2 = .19, R2 = .23, R2 = .18, R2 = .35,
the entire model P < .001 P < .001 P < .001 P < .001
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requires repeated cortisol measurements throughout the
day [54]. We were able to control for factors like age,
menopausal state and life style but we could not control for
others, particularly for the awakening time influencing
morning cortisol rise [59]. It therefore would be important
to replicate our hemostatic findings with strict reference to
the time of awakening and in relation to diurnal cortisol
activity. Moreover, we did not use a high-sensitive assay to
measure CRP which is the gold standard in nowadays
cardiovascular risk assessment [60]. Although statistically
significant, effect sizes of the relationships between cortisol
and VWF and fibrinogen on the one hand and between vital
exhaustion and FVIIa on the other were small. It therefore
remains to be seen whether these associations are of clin-
ical importance. We investigated women with stable CAD
when the acute physiological stress response to the event
was assumed to have abated. We therefore are unable to
state to which extent cortisol would relate to hemostatic
activity in the early phase of an AMI when cortisol levels
are highest. We also do not know whether the relationship
between cortisol and hemostasis will sustain for longer
than half-a-year after the event. This seems important as it
can be assumed that the longer this relationship is main-
tained the greater the harm exerted on coronary arteries in
the long run. Caution is needed in generalizing our findings
across gender because our data could or could not be un-
ique to women with CAD. Future studies may also want to
investigate whether the relationship between endogenous
cortisol levels and prothrombotic activity is specific to
CAD populations or can also be observed in individuals
free of cardiovascular disease.
Taken together, our findings suggest that cortisol levels
could contribute to prothrombotic activity in women with
stable CAD providing one explanation for the empirical
observation relating circulating cortisol to atherosclerotic
vessel damage.
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